Literature DB >> 17038955

Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas.

Alfred T Ogden1, David Horgan, Allen Waziri, David Anderson, Joseph Louca, Guy M McKhann, Michael B Sisti, Andrew T Parsa, Jeffrey N Bruce.   

Abstract

OBJECTIVE: Better characterization of the changes that occur in the circulating monocytes of patients with glioblastoma has become more important recently as monocyte-derived dendritic cells are used as adjuvants in the development of glioma vaccines. This study seeks to develop understanding of the phenotypic changes that occur in circulating monocytes of patients with intracranial cancer and to assess the ability of these cells to differentiate into mature dendritic cells.
METHODS: Monocyte expression levels of HLA-ABC, HLA-DR, CD86, ICAM-1, TNFRII, and GMCSFR were compared between three cohorts: patients with intracranial glioblastoma (n = 15), patients with intracranial metastases (n = 9), and a group of healthy controls (n = 10). Monocytes were then tested for their ability to differentiate into mature dentritic cells based on morphology, CD83 expression and high levels of co-stimulatory molecules.
RESULTS: Comprehensive analysis of monocyte receptor expression demonstrated significantly reduced HLA-ABC, HLA-DR, CD86, ICAM-1, and TNFRII in patients with glioblastoma but not in patients with intracranial metastases compared with a group of healthy controls. GMCSFR expression was significantly reduced in both patients with glioblastoma and intracranial metastases. Additionally, the monocytes of patients with glioblastoma showed a reduced capacity to differentiate into mature dendritic cells as identified by CD83 expression, receptor expression, and morphology.
CONCLUSION: Peripheral monocytes are phenotypically altered in the setting of glioblastoma and display a reduced functional capacity to differentiate into mature dendritic cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038955     DOI: 10.1227/01.NEU.0000233907.03070.7B

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  15 in total

1.  Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.

Authors:  Martin K Hunn; Evelyn Bauer; Catherine E Wood; Olivier Gasser; Marina Dzhelali; Lindsay R Ancelet; Brigitta Mester; Katrina J Sharples; Michael P Findlay; David A Hamilton; Ian F Hermans
Journal:  J Neurooncol       Date:  2014-10-31       Impact factor: 4.130

2.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

Authors:  Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

3.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

Authors:  Hideho Okada; Pawel Kalinski; Ryo Ueda; Aki Hoji; Gary Kohanbash; Teresa E Donegan; Arlan H Mintz; Johnathan A Engh; David L Bartlett; Charles K Brown; Herbert Zeh; Matthew P Holtzman; Todd A Reinhart; Theresa L Whiteside; Lisa H Butterfield; Ronald L Hamilton; Douglas M Potter; Ian F Pollack; Andres M Salazar; Frank S Lieberman
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

4.  Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.

Authors:  Jennifer C Rodrigues; Guido C Gonzalez; Lei Zhang; George Ibrahim; John J Kelly; Michael P Gustafson; Yi Lin; Allan B Dietz; Peter A Forsyth; V Wee Yong; Ian F Parney
Journal:  Neuro Oncol       Date:  2009-12-22       Impact factor: 12.300

Review 5.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04

Review 6.  Improving vaccine efficacy against malignant glioma.

Authors:  Erik Ladomersky; Matthew Genet; Lijie Zhai; Galina Gritsina; Kristen L Lauing; Rishi R Lulla; Jason Fangusaro; Alicia Lenzen; Priya Kumthekar; Jeffrey J Raizer; David C Binder; C David James; Derek A Wainwright
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

7.  Dynamics of central and peripheral immunomodulation in a murine glioma model.

Authors:  Benjamin C Kennedy; Lisa M Maier; Randy D'Amico; Christopher E Mandigo; Elizabeth J Fontana; Allen Waziri; Marcela C Assanah; Peter Canoll; Richard C E Anderson; David E Anderson; Jeffrey N Bruce
Journal:  BMC Immunol       Date:  2009-02-18       Impact factor: 3.615

8.  Therapeutic vaccines for malignant brain tumors.

Authors:  Michael P Gustafson; Keith L Knutson; Allan B Dietz
Journal:  Biologics       Date:  2008-12

9.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

10.  Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part II: combination with external radiation improves survival.

Authors:  Sergiy V Kushchayev; Tejas Sankar; Laura L Eggink; Yevgeniya S Kushchayeva; Philip C Wiener; J Kenneth Hoober; Jennifer Eschbacher; Ruolan Liu; Fu-Dong Shi; Mohammed G Abdelwahab; Adrienne C Scheck; Mark C Preul
Journal:  Cancer Manag Res       Date:  2012-09-17       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.